Systematic Review and Meta-Analyses of Incidence for Group B Streptococcus Disease in Infants and Antimicrobial Resistance, China

Emerg Infect Dis. 2020 Nov;26(11):2651-2659. doi: 10.3201/eid2611.181414.

Abstract

We performed a systematic review and meta-analysis of the incidence, case-fatality rate (CFR), isolate antimicrobial resistance patterns, and serotype and sequence type distributions for invasive group B Streptococcus (GBS) disease in infants <1-89 days of age in China. We searched the PubMed/Medline, Embase, Wanfang, and China National Knowledge Infrastructure databases for research published during January 1, 2000-March 16, 2018, and identified 64 studies. Quality of included studies was assessed by using Cochrane tools. Incidence and CFR were estimated by using random-effects meta-analyses. Overall incidence was 0.55 (95% CI 0.35-0.74) cases/1,000 live births, and the CFR was 5% (95% CI 3%-6%). Incidence of GBS in young infants in China was higher than the estimated global incidence (0.49 cases/1,000 live births) and higher than previous estimates for Asia (0.3 cases/1,000 live births). Our findings suggest that implementation of additional GBS prevention efforts in China, including maternal vaccination, could be beneficial.

Keywords: China; GBS; antimicrobial resistance; bacteria; case-fatality rate; group B Streptococcus; group B Streptococcus disease; infants; meta-analyses; newborns; respiratory infections; streptococci; systematic review.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't
  • Systematic Review

MeSH terms

  • Anti-Bacterial Agents* / pharmacology
  • China / epidemiology
  • Drug Resistance, Bacterial*
  • Humans
  • Incidence
  • Infant
  • Streptococcal Infections* / epidemiology
  • Streptococcus agalactiae / drug effects

Substances

  • Anti-Bacterial Agents